Celiac Disease - Pipeline Assessment and Market Forecasts to 2019

Celiac Disease - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, 'Celiac Disease - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Celiac Disease Therapeutics market. The report identifies the key trends shaping and driving the global Celiac Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Celiac Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Celiac Disease Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Celiac Disease Therapeutics market revenues data from 2006 to 2010, forecast for nine years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Celiac Disease Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Celiac Disease Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Celiac Disease Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Celiac Disease Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Celiac Disease Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Celiac Disease Therapeutics market landscape? – Identify, understand and capitalize.

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 CELIAC DISEASE MARKET - INTRODUCTION

2.1 Overview
2.2 Etiology and Pathophysiology
2.3 Risk Factors
2.4 Sign and Symptoms
  2.4.1 Classical Celiac Disease
  2.4.2 Subclinical Celiac Disease
  2.4.3 Asymptomatic Celiac Disease
  2.4.4 Potential/Latent Celiac Disease
2.5 Associated Conditions
  2.5.1 Malignant Disease
  2.5.2 Osteoporosis
  2.5.3 Infertility
  2.5.4 Autoimmune Disorders
  2.5.5 Dermatitis Herpetiformis
2.6 Refractory Celiac Disease
2.7 Epidemiology
2.8 Diagnosis
  2.8.1 Serological Tests
  2.8.2 Endoscopy
  2.8.3 Small Intestinal Biopsy
2.9 Treatment and Management Pattern
  2.9.1 Natural Gluten-free Diet
  2.9.2 Dietary Supplements
  2.9.3 Management of Complications and Associated Conditions
2.10 GlobalData Pipeline Report Guidance

3 CELIAC DISEASE - MARKET CHARACTERIZATION

3.1 Major Markets, Market Forecast (2017 - 2019)
3.2 Celiac Disease Therapeutics Market Forecast (2017-2019) - The US
3.3 Celiac Disease Therapeutics Market Forecast (2017-2019) - France
3.4 Celiac Disease Therapeutics Market Forecast (2017-2019) - Germany
3.5 Celiac Disease Therapeutics Market Forecast (2017-2019) - Italy
3.6 Celiac Disease Therapeutics Market Forecast (2017-2019) - Spain
3.7 Celiac Disease Therapeutics Market Forecast (2017-2019) - The UK
3.8 Celiac Disease Therapeutics Market Forecast (2017-2019) - Japan
3.9 Drivers and Barriers for the Celiac Disease Therapeutics Market
  3.9.1 Drivers for the Celiac Disease Therapeutics Market
  3.9.2 Barriers for the Celiac disease Therapeutics Market
3.10 Opportunity and Unmet Need Analysis
3.11 Key Takeaway

4 CELIAC DISEASE THERAPEUTICS - PIPELINE ASSESSMENT

4.1 Overview
4.2 Strategic Pipeline Assessment
4.3 Celiac Disease Therapeutics Pipeline - Pipeline by Phases of Development
  4.3.1 Celiac Disease Therapeutics - Phase II Pipeline
  4.3.2 Celiac Disease Therapeutics - Phase I Pipeline
  4.3.3 Celiac Disease Therapeutics - Preclinical Pipeline
  4.3.4 Celiac Disease Therapeutics - Discovery Pipeline
4.4 Celiac Disease Therapeutics - Pipeline by Mechanism of Action
4.5 Technology Trends Analytic Framework
4.6 Molecule Profile for Drugs Under Phase II and Phase I Clinical Development
  4.6.1 ALV003
  4.6.2 Larazotide acetate (AT1001)
  4.6.3 Nexvax2
4.7 Potential Targets for Development of Drugs for Celiac Disease
  4.7.1 Reduction in Gluten Exposure
  4.7.2 Decrease in Intestinal Permeability
  4.7.3 Suppression of Immune Response
4.8 Challenges in Development of Drugs for Celiac Disease
  4.8.1 Lack of Awareness
  4.8.2 Unavailability of Suitable Animal Models for Pre-clinical Studies
  4.8.3 Challenges in Designing Clinical Trials
  4.8.4 Limitations of Diagnostic Methods to Access Therapeutic Response
4.9 Key Takeaway

5 CELIAC DISEASE THERAPEUTICS - CLINICAL TRIALS MAPPING

5.1 Clinical Trials by Country (US, EU5 and Japan)
5.2 Clinical Trials by Phase
5.3 Clinical Trials by Trial Status
5.4 Overall Sponsors
5.5 Prominent Sponsors
5.6 Top Companies Participating in Celiac Disease Therapeutics Clinical Trials

6 CELIAC DISEASE THERAPEUTICS - FUTURE PLAYERS

6.1 Introduction
6.2 Company Profiles
  6.2.1 Alba Therapeutics Corporation
  6.2.2 Alvine Pharmaceuticals Inc.

7 CELIAC DISEASE THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS

8 CELIAC DISEASE THERAPEUTICS - APPENDIX

8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
  8.3.1 Coverage
  8.3.2 Secondary Research
  8.3.3 Forecasting
  8.3.4 Primary Research
  8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Bibliography

LIST OF TABLES

Table 1: Marsh’s Classification of Small Intestinal lesions
Table 2: Disorders Associated with Celiac Disease
Table 3: Prevalence of Celiac disease
Table 4: Serological Tests in Celiac Disease
Table 5: Celiac Disease Therapeutics Market, Major Markets, Forecast ($m), 2017 - 2019
Table 6: Celiac Disease Therapeutics Market, The US, Forecast ($m), 2017 - 2019
Table 7: Celiac Disease Therapeutics Market, France, Forecast ($m), 2017 - 2019
Table 8: Celiac Disease Therapeutics Market, Germany, Forecast ($m), 2017 - 2019
Table 9: Celiac Disease Therapeutics Market, Italy, Forecast ($m), 2017 - 2019
Table 10: Celiac Disease Therapeutics Market, Spain, Forecast ($m), 2017 - 2019
Table 11: Celiac Disease Therapeutics Market, The UK, Forecast ($m), 2017 - 2019
Table 12: Celiac Disease Therapeutics Market, Japan, Forecast ($000s), 2017 - 2019
Table 13: Celiac Disease Therapeutics - Phase II Pipeline, 2011
Table 14: Celiac Disease Therapeutics - Phase I Pipeline, 2011
Table 15: Celiac Disease Therapeutics - Preclinical Pipeline, 2011
Table 16: Celiac Disease Therapeutics - Discovery Pipeline, 2011
Table 17: Celiac Disease Therapeutics - Clinical Trials by Phase, 2011
Table 18: Celiac Disease Therapeutics - Clinical Trials by Status, 2011
Table 19: Celiac Disease Therapeutics - Prominent Sponsors, 2011
Table 20: Celiac Disease Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 21: Alba Therapeutics Corporation - Gastrointestinal and Immunology Pipeline, 2011
Table 22: Alvine Pharmaceuticals, Inc - Gastrointestinal and Immunology Pipeline, 2011
Table 23: Celiac Disease Therapeutics: Licensing and Partnership Deals

LIST OF FIGURES

Figure 1: Appearance of Healthy Intestinal Villi and Villi in Celiac Disease
Figure 2: Taxonomy of Cereals Which can be used by Celiac Disease Patients
Figure 3: Flow Diagram of Disease Progression
Figure 4: Pathophysiology of Celiac Disease
Figure 5: Marsh’s Classification of Small Intestine Lesions
Figure 6: Iceberg Presentation of Celiac Disease
Figure 7: Diagnosis of Celiac Disease- Flow Chart
Figure 8: Celiac Disease Therapeutics Market, Major Markets, Forecast ($m), 2017 - 2019
Figure 9: Celiac Disease Therapeutics Market, The US, Forecast ($m), 2017 - 2019
Figure 10: Celiac Disease Therapeutics Market, France, Forecast ($m), 2017 - 2019
Figure 11: Celiac Disease Therapeutics Market, Germany, Forecast ($m), 2017 - 2019
Figure 12: Celiac Disease Therapeutics Market, Italy, Forecast ($m), 2017 - 2019
Figure 13: Celiac Disease Therapeutics Market, Spain, Forecast ($m), 2017 - 2019
Figure 14: Celiac Disease Therapeutics Market, The UK, Forecast ($m), 2017 - 2019
Figure 15: Celiac Disease Therapeutics Market, Japan, Forecast ($000s), 2017 - 2019
Figure 16: Celiac Disease Therapeutics - Pipeline by Phases of Development, 2011
Figure 17: Celiac Disease Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 18: Celiac Disease Therapeutics - Technology Trends Analytics Framework, 2011
Figure 19: Celiac Disease Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 20: Potential Targets for Drug Development for Celiac Disease
Figure 21: Celiac Disease Therapeutics - Clinical Trials by Phase, 2011
Figure 22: Celiac Disease Therapeutics - Clinical Trials by Status, 2011
Figure 23: Celiac Disease Therapeutics - Prominent Sponsors, 2011
Figure 24: Celiac Disease Therapeutic Clinical Trials - Company Sponsors by Phase, 2011
Figure 25: Celiac Disease Therapeutics - Pipeline by Company, 2011
Figure 26: GlobalData Market Forecasting Model

COMPANIES MENTIONED

Alba Therapeutics Corporation
Alvine Pharmaceuticals Inc. Skip to top